Premium
Thalidomide ( N ‐phthaloylglutamimide> in the treatment of advanced cancer
Author(s) -
Olson Kenneth B.,
Hall Thomas C.,
Horton John,
Khung Christiaan L.
Publication year - 1965
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196563292
Subject(s) - thalidomide , medicine , sedation , cancer , oncology , surgery , multiple myeloma
Thalidomide (N‐phthaloylglutamimide) was administered to 21 patients with fourteen types of cancer for periods of 1 to 34 weeks, with total doses ranging from 4.2 to 354.0 Gm. There were mild hemologic and neurological untoward effects. Notumor regression was noted but there was significant subjective palliation in 7 patients. Further study of this drug in patients with advanced cancer is warranted. Palliation was noted to be chiefly improved sedation in disturbed and elderly persons. There was possible arrest of previously rapid growth of tumor in 2 cases.